Equities

Neurosense Therapeutics Ltd

NRSN:NAQ

Neurosense Therapeutics Ltd

Actions
  • Price (USD)0.92
  • Today's Change-0.070 / -7.08%
  • Shares traded143.52k
  • 1 Year change+76.99%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Neurosense Therapeutics Ltd have a median target of 5.25, with a high estimate of 7.50 and a low estimate of 3.00. The median estimate represents a 470.65% increase from the last price of 0.92.
High715.2%7.50
Med470.7%5.25
Low226.1%3.00

Earnings history & estimates in USD

On Oct 01, 2024, Neurosense Therapeutics Ltd reported 2nd quarter 2024 losses of -0.02 per share. This result exceeded the -0.20 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 95.45%.
The next earnings announcement is expected on Dec 02, 2024.
Average growth rate-12.23%
Neurosense Therapeutics Ltd reported annual 2023 losses of -0.83 per share on Apr 04, 2024.
Average growth rate-27.69%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.